0

The risk of fetal anomalies as a result of progesterone therapy during pregnancy

Check JH et al., 1986

Fertility and sterility, 45(4), 575-577

DOI 10.1016/s0015-0282(16)49292-7 PMID 3956772 Source

Abstract

The incidence of congenital anomalies in infants born to 382 women treated with P was noted. Only five anomalies occurred in the infants born to women who had taken P. This study supports the data of Rock et al. by demonstrating a similar low incidence of birth defects in a much larger series of patients who also took a much higher dosage of P. Similarly, because only 1 of 189 patients treated with both P and 17-OHP developed anomalies, the data supports the study by Katz et al., suggesting no increase in anomalies related to 17-OHP therapy.

Topics

Reproductive Endocrinology > Progesterone > SupplementationPregnancy > Outcomes > ComplicationsReproductive Endocrinology > Luteal Phase > Support
progesterone therapy pregnancy safety, progesterone birth defects risk, congenital anomalies progesterone supplementation, first trimester progesterone safety, 17-ohp pregnancy safety data, progesterone miscarriage prevention safety, luteal support progesterone risks, progesterone supplementation fetal outcomes, hydroxyprogesterone congenital anomalies, progesterone dosage pregnancy safety, vaginal progesterone birth defects, luteal phase support safety profile

Cite this article

Check, J. H., Rankin, A., & Teichman, M. (1986). The risk of fetal anomalies as a result of progesterone therapy during pregnancy. *Fertility and sterility*, *45*(4), 575-577. https://doi.org/10.1016/s0015-0282(16)49292-7

Keywords

17-alpha-Hydroxyprogesterone, Abnormalities, Drug-Induced, Abortion, Spontaneous, Drug Therapy, Combination, Female, Humans, Hydroxyprogesterones, Infant, Newborn, Injections, Intramuscular, Pregnancy, Pregnancy Trimester, First, Progesterone, Retrospective Studies, Risk, Suppositories, Surveys and Questionnaires, Vagina

Related articles